By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site ...

Biogen has announced that the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) have started ...

An investigational higher dose of spinal muscular atrophy drug nusinersen gains attention as the FDA and European Medicines ...

Biogen’s applications for the higher dose regimen of spinal muscular atrophy (SMA) drug Spinraza are now under review in the US and Europe.

Spinal muscular atrophy (SMA) It refers to a group of ... form is caused by a mutated or missing gene known as the survival motor neuron gene 1 (SMN1), which causes the neurons to deteriorate ...

Analytics company GlobalData has shared its optimism regarding the future of Novartis’ spinal muscular atrophy ... biallelic mutations in the survival motor neuron 1 (SMN1) gene.

Laboratory tests can monitor for renal toxicity and coagulation abnormalities, including acute severe low platelet counts, which have been observed after administration of some ASOs. Biogen licensed ...

Investing.com -- Shares of Ionis Pharmaceuticals (NASDAQ: IONS) climbed 7% today after the company announced that regulatory agencies in the United States and Europe have accepted applications for a ...

SPINRAZA, the brand name for nusinersen, is an antisense oligonucleotide (ASO) that increases the production of full-length survival motor neuron (SMN) protein, essential for motor neuron health.